Table 1.

Definition of prognostic risk groups, Concin N, et al. Int J Gynecol Cancer 2020.

Risk Group	Molecular Classification Unknown	Molecular Classification Known
Low	Stage IA endometrioid + low-grade (G1-2) + LVSI negative or focal	Stage I–II POLEmut, no residual disease Stage IA MMRd/NSMP endometrioid + low-grade (G1-2) + LVSI negative or focal
Intermediate	Stage IB endometrioid + low-grade (G1-2) + LVSI negative or focal Stage IA endometrioid + high-grade (G3) + LVSI negative or focal Stage IA non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) without myometrial invasion.	Stage IB MMRd/NSMP endometrioid + low-grade (G1-2) + LVSI negative or focal Stage IA MMRd/NSMP endometrioid + high-grade (G3) + LVSI negative or focal Stage IA p53abn and/or non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) without myometrial invasion
High-intermediate	Stage I endometrioid + substantial LVSI regardless of grade and depth of invasion. Stage IB endometrioid high-grade G3 regardless of LVSI status Stage II	Stage I MMRd/NSMP endometrioid + substantial LVSI regardless of grade and depth of invasion Stage IB MMRd/NSMP endometrioid high-grade G3 regardless of LVSI status Stage II MMRd/NSMP endometrioid.
High	Stage III–IVA with no residual disease Stage I–IVA non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) with myometrial invasion, and with no residual disease.	Stage III–IVA MMRd/NSMP endometrioid, with no residual disease Stage I–IVA p53abn endometrial with myometrial invasion, with no residual disease Stage I–IVA NSMP/MMRd serous, undifferentiated carcinoma, carcinosarcoma with myometrial invasion, with no residual disease
Advanced disease	Stage III–IVA with residual disease Stage IVB	Stage III–IVA with residual disease of any molecular type Stage IVB of any molecular type